Aptose生物科学 APTO 深 沪
等待开盘 04-01 09:30:00 美东时间
1.71
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.71
- 总市值 436.46万
- 52周最高 42.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.35
- 委 比 0.00%
- 总股本 255.24万
- 历史最高 5032.80
- 量 比 0
- 振 幅 0.00%
- 历史最低 3.30
- 每 手 1
- 风险率 0.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aptose Shareholders Approve Hanmi Go‑Private Acquisition Plan
Aptose Biosciences ( ($TSE:APS) ) has shared an update. On March 31, 2026, Apto...
今天 11:53
ISS Backs Hanmi’s Cash Takeover of Aptose Ahead of March 31 Vote
Aptose Biosciences ( ($TSE:APS) ) has issued an announcement. Aptose Bioscience...
03-19 20:14
ISS urges Aptose shareholders to back Hanmi deal at CAD 2.41 per share
ISS urges Aptose shareholders to back Hanmi deal at CAD 2.41 per share ISS recommended Aptose shareholders vote FOR a special resolution to approve the proposed arrangement under which Hanmi and its subsidiary would acquire the shares they do not already own. The recommendation cited a C$2.41 per-sh
03-19 19:30
Aptose Sets March 2026 Vote on C$2.41‑per‑Share Hanmi Takeover
New activity is brewing for Aptose Biosciences ( ($TSE:APS) ). The company has ...
02-24 19:48
Aptose Reschedules Special Meeting on Hanmi Acquisition Plan
Aptose Biosciences ( ($TSE:APS) ) has issued an announcement. On December 19, 2...
2025-12-20 06:52
Aptose Biosciences Unveils Promising AML Therapy Data
The latest update is out from Aptose Biosciences ( ($TSE:APS) ). On December 6,...
2025-12-08 20:50
Aptose Biosciences Reports 100% Response Rate in AML Trial With Tuspetinib Combination Therapy
Aptose Biosciences Inc. announced updated clinical data for its lead compound tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA), presented at the 67th American Society of Hem...
2025-12-06 21:00
BRIEF-Aptose Biosciences Announces Arrangement Agreement For Acquisition By Hanmi Pharmaceutical
Nov 19 (Reuters) - Aptose Biosciences Inc APS.TO: APTOSE BIOSCIENCES ANNOUNCES ARRANGEMENT AGREEMENT FOR ACQUISITION BY HANMI PHARMACEUTICAL APTOSE BIOSCIENCES INC - SHAREHOLDERS TO RECEIVE C$2.41 PER...
2025-11-19 14:23
Aptose Biosciences GAAP EPS of -$2.01
Aptose Biosciences press release (OTC:APTOF): Q3 GAAP EPS of -$2.01. Total cash, cash equivalents and restricted cash equivalents as of September 30, 2025 were $1.6 million. The Company does not have ...
2025-11-14 14:11
Aptose Biosciences Q3 EPS $(2.01) Misses $(1.95) Estimate
Aptose Biosciences (TSX:APS) reported quarterly losses of $(2.01) per share which missed the analyst consensus estimate of $(1.95) by 3.08 percent. This is a 81.89 percent increase over losses of $(11.10) per share from
2025-11-14 06:21
